Factors Influencing Discrepancies Between the QuantiFERON-TB Gold in Tube Test and the Tuberculin Skin Test in Korean Patients with Rheumatic Diseases

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 4, 2013, Pages 424-432

  Kim, Jae Hoon ^a   Cho, Soo Kyung ^a   Han, Minkyung ^a   Choi, Chan Bum ^a   Kim, Tae Hwan ^a   Jun, Jae Bum ^a   Bae, Sang Cheol ^a   Yoo, Dae Hyun ^a   Sung, Yoon Kyoung ^a  

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANALYTICAL EQUIPMENT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DRUG USE; ETHNIC GROUP; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; JUVENILE RHEUMATOID ARTHRITIS; KOREAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCREENING; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84873736775     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.07.001     Document Type: Article

References (30)

1. Bouza E., Moya J.G., Muñoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001, 15:335-361.
2. Carmona L., Hernández-García C., Vadillo C., Pato E., Balsa A., González-Alvaro I., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003, 30:1436-1439.
3. Kim E.M., Uhm W.S., Bae S.C., Yoo D.H., Kim T.H. Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 2011, 38:2218-2223.
4. Kievit W., Fransen J., Adang E.M., den Broeder A.A., Bernelot Moens H.J., Visser H., et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: Results from the Dutch Rheumatoid Arthritis monitoring register. Rheumatology (Oxford) 2011, 50:196-203.
5. Moiton M.P., Richez C., Dumoulin C., Mehsen N., Dehais J., Schaeverbeke T. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections. Clin Microbiol Infect 2006, 12:1151-1153.
6. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006, 2:602-610.
7. Hamdi H., Mariette X., Godot V., Weldingh K., Hamid A.M., Prejean M.V., et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006, 8:R114.
8. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., Wallis R.S. Tumor-necrosis-factor blockers: Differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486-492.
9. Ledingham J., Wilkinson C., Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-alpha treatments. Rheumatol Oxf Engl 2005, 44:1205-1206.
10. Mariette X., Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003, 62:791.
11. Martin J., Walsh C., Gibbs A., McDonnell T., Fearon U., Keane J., et al. Comparison of interferon γ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010, 69:181-185.
12. Kang Y.A., Lee H.W., Yoon H.I., Cho B., Han S.K., Shim Y.S., et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005, 293:2756-2761.
13. Moon H.W., Kim H., Hur M., Yun Y.M., Lee A. Latent tuberculosis infection screening for laboratory personnel using interferon-γ release assay and tuberculin skin test in Korea: An intermediate incidence setting. J Clin Lab Anal 2011, 25:382-388.
14. Talebi-Taher M., Javad-Moosavi S.A., Entezari A.H., Shekarabi M., Parhizkar B. Comparing the performance of QuantiFERON-TB gold and Mantoux test in detecting latent tuberculosis infection among Iranian health care workers. Int J Occup Med Environ Health 2011, 24:359-366.
15. Mazurek G.H., Jereb J., Vernon A., LoBue P., Goldberg S., Castro K., et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States. MMWR Recomm Rep 2010, 59:1-25.
16. Carmona L., Gómez-Reino J.J., Rodríguez-Valverde V., Montero D., Pascual-Gómez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
17. Ponce de León D., Acevedo-Vásquez E., Sánchez-Torres A., Cucho M., Alfaro J., Perich R., et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005, 64:1360-1361.
18. Mow W.S., Abreu-Martin M.T., Papadakis K.A., Pitchon H.E., Targan S.R., Vasiliauskas E.A. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004, 2:309-313.
19. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000, 49:1-51. American Thoracic Society.
20. Pai M., Riley L.W., Colford J.M. Interferon-gamma assays in the immunodiagnosis of tuberculosis: A systematic review. Lancet Infect Dis 2004, 4:761-776.
21. Jasmer R.M., Nahid P., Hopewell P.C. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002, 347:1860-1866.
22. Hoffmann H., Loytved G., Bodmer T. Interferon-gamma release assays in tuberculosis diagnostics. Internist (Berl) 2007, 48:497-498.
23. Mazurek G.H., Villarino M.E. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR Recomm Rep 2003, 52:15-18. Centers for Disease Control and Prevention.
24. Inanc N., Aydin S.Z., Karakurt S., Atagunduz P., Yavuz S., Direskeneli H. Agreement between QuantiFERON-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009, 36:2675-2681.
25. Global tuberculosis control: Epidemiology, strategy, financing, WHO Report 2009 2009, World Health Organization, World Health Organization, Geneva.
26. Hong Y.P., Kim S.J., Lew W.J., Lee E.K., Han Y.C. The seventh nationwide tuberculosis prevalence survey in Korea. Int J Tuberc Lung Dis 1995, 1998(2):27-36.
27. Chun J.K., Kim C.K., Kim H.S., Jung G.Y., Lee T.J., Kim K.H., et al. The role of a whole blood interferon-gamma assay for the detection of latent tuberculosis infection in Bacille Calmette-Guérin vaccinated children. Diagn Microbiol Infect Dis 2008, 62:389-394.
28. Kang Y.A., Lee H.W., Yoon H.I., Cho B., Han S.K., Shim Y.S., et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005, 293:2756-2761.
29. Kim E.Y., Lim J.E., Jung J.Y., Son J.Y., Lee K.J., Yoon Y.W., et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009, 9:207.
30. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.